Back to today’s briefing

Story perspectives

Experts Skeptical of Trump's Drug Price Reduction Plan

10/19/2025

47 6 Full Breakdown

Summary

Story summary

Experts doubt President Donald Trump's plan to lower pharmaceutical prices will reduce costs.
The plan includes a deal with Pfizer to align Medicaid prices with other developed countries.
Economists note Medicaid already pays prices similar to European counterparts, which limits gains.
Proposed branded-drug tariffs could raise prices, especially for generics.
TrumpRx is unlikely to shift the market, as few consumers buy medications directly.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act, enacted on December 8, 2003, under President George W. Bush, introduced Medicare Part D, providing drug coverage to over 40 million seniors. This legislation prohibited Medicare from negotiating prices, leading to ongoing debates about drug affordability and pricing strategies, echoing past efforts like the 2022 Inflation Reduction Act's provisions for price negotiations.

1 of 2

Story summary

Experts doubt President Donald Trump's plan to lower pharmaceutical prices will reduce costs.
The plan includes a deal with Pfizer to align Medicaid prices with other developed countries.
Economists note Medicaid already pays prices similar to European counterparts, which limits gains.
Proposed branded-drug tariffs could raise prices, especially for generics.
TrumpRx is unlikely to shift the market, as few consumers buy medications directly.

1 / 2